

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**吉林省輝南長龍生化藥業股份有限公司**  
**Jilin Province Huinan Changlong Bio-pharmacy Company Limited**

*(a joint stock limited company incorporated in the People's Republic of China)*

**(Stock Code: 8049)**

**THE PASSING OF INDEPENDENT NON-EXECUTIVE DIRECTOR  
AND  
CHANGES IN COMPOSITION OF BOARD COMMITTEES**

**THE PASSING OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board of directors (the **"Board"**) of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the **"Company"**) hereby announces with profound sorrow that the Board was notified on 14 October 2026 of the recent passing of Mr. Gao Qipin ("Mr. Gao"), an independent non-executive director of the Company.

Mr. Gao also served as the chairman of the audit committee (the "Audit Committee"), the chairman of the remuneration committee and the chairman of the nomination committee of the Company.

The Board would like to express its sincere gratitude to Mr. Gao for his valuable contributions to the Company during his tenure of office. All members of the Board express their deepest sorrow upon the passing of Mr. Gao.

**NON-COMPLIANCE WITH THE GEM LISTING RULES**

Following the passing of Mr. Gao, the number of independent non-executive directors of the Company has reduced to two, which results in the Company's non-compliance with the following requirements of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"):

1. Rule 5.05(1) of the GEM Listing Rules, which requires the Board to include at least three independent non-executive directors;
2. Rule 5.05A of the GEM Listing Rules, which requires the independent non-executive directors to represent at least one-third of the Board;
3. Rule 5.28 of the GEM Listing Rules, which requires the Audit Committee to comprise a minimum of three members;
4. Rule 5.34 of the GEM Listing Rules, which requires the remuneration committee to be chaired by an independent non-executive director; and
5. Rule 5.36A of the GEM Listing Rules, which requires the nomination committee to be chaired by the chairman of the Board or an independent non-executive director.

## IDENTIFICATION OF NEW INDEPENDENT NON-EXECUTIVE DIRECTOR

Pursuant to Rules 5.06, 5.33, 5.36 and 5.36C of the GEM Listing Rules, the Company is required to appoint a sufficient number of independent non-executive directors and fill the vacancies in the relevant Board committees within three months from the date of non-compliance.

The Board is currently identifying a suitable candidate and will make its best endeavors to appoint a new independent non-executive director and fill the vacancies in the relevant Board committees as soon as practicable (and in any event within three months). The Company will make further announcement(s) in relation to the relevant appointments as and when appropriate.

By order of the Board  
**Jilin Province Huinan Changlong Bio-pharmacy Company Limited**  
**Zhang Yi**  
*Chairman*

Jilin Province, the PRC, 16 October 2026

*As at the date of this announcement, the Board comprises five executive directors, being Zhang Yi, Xu Xiang Fu, Wang Wei, Chi Chun Hong and Li Ning; and two independent non-executive directors, being Bai Jun Gui and Tian Jie.*

*This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the “Latest Listed Company Announcements” page on the Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its posting.*